Cleft palate is one of the most common human birth defects and is associated with multiple genetic and environmental risk factors. Although mutations in the genes encoding transforming growth factor beta (TGFβ) signaling molecules and interferon regulatory factor 6 (Irf6) have been identified as genetic risk factors for cleft palate, little is known about the relationship between TGFβ signaling and IRF6 activity during palate formation. Here, we show that TGFβ signaling regulates expression of Irf6 and the fate of the medial edge epithelium (MEE) during palatal fusion in mice. Haploinsufficiency of Irf6 in mice with basal epithelial-specific deletion of the TGFβ signaling mediator Smad4 (Smad4 
INTRODUCTION
Cleft palate is a serious and common craniofacial birth defect affecting millions of people worldwide (Mossey et al., 2009; Wong and Hagg, 2004) . Cleft palate has ethnic and geographic variations in prevalence, and it affects feeding, swallowing, speech, hearing, middle-ear ventilation, respiration and appearance (Iwata et al., 2011) . Studies in mouse models and genetic screening in humans have implicated several factors in syndromic cleft palate, such as IRF6 mutation in Van der Woude syndrome (VWS) and popliteal pterygium syndrome (PPS), SMAD4 mutation in juvenile polyposis syndrome, and TGFBR1 or TGFBR2 mutation in Loeys-Dietz syndrome (previously called Marfan syndrome type II). Mutations in TGFB3, IRF6, CYP (cytochrome P450), MSX1 and TBX10 have also been associated with non-syndromic cleft lip with or without cleft palate (NSCL/P) (Iwata et al., 2011) . In addition, polymorphic variants associated with NSCL/P within human chromosomes 1q32 (IRF6), 1p22 (ABCA4), 8q24.21, 10q25 (VAX1), 17q22 and 20q12 (MAFB) have been identified by genome-wide association studies . Thus, mutations in IRF6, SMAD4 and TGFBR2 confer a significant attributable risk for cleft palate.
TGFβ signaling is one of the major signaling cascades crucial for craniofacial development (Iwata et al., 2011) . Epithelial-specific deletion of Tgfbr2 (Tgfbr2 fl/fl ;K14-Cre) in mice results in persistence of the medial edge epithelium (MEE) and submucous cleft palate (Xu et al., 2006) . TGFβ transmits signals through a membrane receptor serine/threonine kinase complex that phosphorylates SMAD2 and SMAD3, followed by the formation of transcriptional complexes with SMAD4 and translocation into the nucleus (Massagué, 2012; Ross and Hill, 2008; Schmierer and Hill, 2007; Shi and Massagué, 2003) . TGFβ also activates SMAD-independent signaling cascades, including mitogen-activated protein kinase (MAPK) pathways, such as p38 MAPK (MAPK14 -Mouse Genome Informatics), under certain physiological and pathological conditions (Kang et al., 2009; Xu et al., 2008; Zhang, 2009) . Studies using SMAD4-deficient cells, or dominant-negative SMADs, support the possibility that MAPK activation is independent of SMADs (Chen et al., 1998; Giehl et al., 2000; Hocevar et al., 1999; Hu et al., 1999) . p38 MAPK activation by TGFβ is accompanied by SMAD-independent, TRAF6 and TAK1 (MAP3K7 -Mouse Genome Informatics) phosphorylation (Iwata et al., 2012; Sorrentino et al., 2008; Yamashita et al., 2008) . The balance between direct activation of SMADs and MAPK pathways often defines cellular responses to TGFβ.
IRF6 belongs to a family of transcription factors that share a highly conserved, helix-turn-helix, DNA-binding domain and a less conserved, protein-binding domain. Among the genes that have been associated with NSCL/P, IRF6 has been implicated in the largest percentage of cases (Koillinen et al., 2005; Srichomthong et al., 2005) . Mutation of IRF6 can lead to the autosomal-dominant conditions VWS and PPS, which are characterized by oral clefting and lower lip pits (Kondo et al., 2002; Moretti et al., 2010) . VWS and PPS are allelic variants of the same condition caused by different mutations of the same gene. PPS includes all the features of VWS, plus popliteal pterygia, syngnathia, distinct toe and nail abnormality, syndactyly and genito-urinary malformations. An arginine 84 to cysteine (R84C) mutation in IRF6 is the most common mutation found in patients with PPS (Richardson et al., 2006) . Although the function of the R84C mutation is still largely RESEARCH ARTICLE TGFβ-mediated Irf6 activity during palatogenesis unknown, recent studies have demonstrated that it results in loss of DNA binding (Kondo et al., 2002; Little et al., 2009 ). The primary defect in Irf6-deficient mice is in keratinocyte differentiation and proliferation. Homozygous Irf6 gt1/gt1 (null) embryos exhibit abnormal skin, limb and craniofacial morphogenesis, including cleft palate (Ingraham et al., 2006) . Mice homozygous for Irf6 R84C , which is an R84C knock-in resulting in expression of mutant IRF6 protein, exhibit a severe intraoral epithelial adhesion caused by a failure of terminal differentiation similar to that in homozygous Irf6 gt1/gt1 (null) embryos (Ingraham et al., 2006; Richardson et al., 2006) .
Despite the established roles of TGFβ signaling and IRF6 activity during palate formation, the interaction between TGFβ signaling and IRF6 activity is poorly understood. In this study, we investigate the interaction between TGFβ signaling and IRF6 activity. We demonstrate that Irf6 and Smad4 interact genetically, and that TGFβ-mediated Irf6 expression is crucial for p21 (CDKN1A -Mouse Genome Informatics) expression and fate determination of the MEE cells during palatal fusion. fl/fl mice. Genotyping was performed using PCR primers as previously described (Ito et al., 2003; Richardson et al., 2009; Xu et al., 2008; Xu et al., 2006) . Human keratin 14 (K14; KRT14 -Human Gene Nomenclature Database) promoter-driven Irf6-encoding transgene was prepared as follows: an EcoRI-HindIII blunted fragment (7.3 kb) encoding mouse Irf6 was subcloned into the BamHI blunted sites of the pGEM 3Z-K14 vector to produce pG3ZK14-Irf6, resulting in a construct containing the K14 promoter (2.1 kb), the β-globin intron (736 bp), the coding sequence for Irf6 (4.1 kb) and the K14 polyadenylation signal (500 bp). The EcoRI-HindIII fragment was isolated free of vector sequence by preparative gel electrophoresis. DNA was further purified using an Elutip column (Schleicher and Schuell, Dessell, Germany) and microinjected in the pronuclei of fertilized oocytes (Jackson/B6D2F F1) following standard procedures. Transgenic founder mice were identified by PCR analysis. PCR amplification of tail genomic DNAs (0.5-1 μg) was performed on a thermal cycler, with 35 cycles consisting of 94°C, 62°C and 72°C for 1 minute each. An aliquot (15 μl) of each reaction was resolved in a 1% agarose gel, and amplified fragments were visualized by ethidium bromide staining. The PCR primers used were 5Ј-TCAGGAGC -AGGTGCACAAGAGTT-3Ј and 5Ј-ACTCGCATCCCTTTCCAATTTAC-3Ј. Irf6 Tg with Tgfbr2 fl/fl mice. Genotyping was performed using PCR primers as previously described (Ito et al., 2003; Xu et al., 2008; Xu et al., 2006) . All mouse experiments were conducted in accordance with protocols approved by the Department of Animal Resources and the Institutional Animal Care and Use Committee of the University of Southern California.
MATERIALS AND METHODS

Animals
Comparative analysis of transcription factor-binding sites
Genomic sequences of the entire human and murine IRF6 (RefSeq accession NM_006147.3/hg19 and NM_016851.2/mm10), p63 (RefSeq accession NM_001114980/hg19 and NM_011641.2/mm10) and CDKN1A/p21 (RefSeq accession NM_000389.4/hg19 and NM_007669.4/mm10) genes were obtained from the University of California, Santa Cruz (UCSC) genome browser, including 2.5 kb upstream and 2.5 kb downstream of the respective transcription start sites (TSSs), based on mouse genome Build 38. These sequences were mapped to seven additional mammalian genomes [chimpanzee (Build 2.1.4), orangutan (Build 2.0.2), rhesus macaque (Build 1.0), human (Build 19), rat (Build 5), dog (Build 3.1) and horse (Build equCab2)] using the BLAT tool. Multiple alignments for these sequences were obtained using the ClustalW2 tool with default parameters and settings (Larkin et al., 2007) . To account for uncertainty in the quality of the horse and dog draft genome sequences, sequence alignments with and without information from these species were performed. Transcription factor-binding motifs relevant to SMAD, p63 (TRP63 -Mouse Genome Informatics) and p38 MAPK pathway elements were searched within and proximal to these genes (i.e. 2.5 kb upstream and 2.5 kb downstream of the mouse TSS for each gene). The recognition sequences searched for SMAD binding were 5Ј-GTCT-3Ј, 5Ј-AGAC-3Ј and 5Ј-GTCTAGAC-3Ј (Denissova et al., 2000; Zawel et al., 1998) and for MEF2 family member binding was 5Ј-YTAWWWWTAR-3Ј (Black and Olson, 1998) . In addition, we evaluated the following potential p63 recognition sites: the canonical p53 family 20-base recognition sequence formed from duplicates of the half-site recognition sequence 5Ј-RRRCWWGYYY-3Ј separated by any combination of 0 to 13 bases (Cai et al., 2012; el-Deiry et al., 1992) and the p63-preferential recognition sequence 5Ј-RRRCRWGYYYRRRC WYGYYY-3Ј (Perez et al., 2007) . To account for the possibility of degenerate p53 family member-binding sites, we used the p53scan and p63scan algorithms with default options , which allow the consensus half-site to vary slightly in composition. Finally, we also searched for the eight-base recognition sequence 5Ј-AANNGAAA-3Ј for the DNA-binding domains of IRF family members (Fujii et al., 1999) and the more specific ten-base recognition sequence 5Ј-AACCGAAACY-3Ј for the IRF6 DNA-binding domain ).
Promoter-proximal search of p53-family responsive elements
The aforementioned consensus recognition sequences of p53 family members (see previous section) were used to search the murine and human p21 genomic sequences for putative p53 and p63 recognition sites proximal to the promoter. Genomic sequences were obtained from the UCSC genome browser, spanning a 5-kb window centered around the transcription start site of each p21 RefSeq transcript variant in the murine genome (build mm10, 2 transcript variants) and human genome (build hg19, 4 transcript variants).
Chromatin immunoprecipitation (ChIP) assay
Back skin was dissected from embryonic day (E) 13.5 C57B6/J mouse embryos in PBS. For the separation of skin epithelium from mesenchyme, the explants were incubated in 0.25% dispase (Invitrogen) for 30 minutes at 37°C. The epithelium was further dissociated in a 0.25% trypsin-EDTA solution for 10 minutes at 37°C, fixed with 1% formaldehyde for 15 minutes at room temperature and lysed in cell lysing buffer (Cell Signaling Technology) with a cocktail of proteinase inhibitors (Ultra Complete Mini, Roche). After pre-clearing treatment, cell extracts were incubated with anti-SMAD4, anti-MEF2 (Cell Signaling Technology), anti-p63 or IgG control (Santa Cruz Biotechnology) antibodies for two hours according to the manufacturer's protocol (Cell Signaling Technology). We assayed for the presence of putative target sites in the immune complexes by PCR using primers amplifying the following genomic regions: mouse Irf6 promoter SMAD-binding site (BS) 1, 5Ј-GCAGGTCCTCGTGCTAGTTC-3Јand 5Ј-CTGCCTCTTCGTCACCCTAC-3Ј; mouse Irf6 promoter SMAD BS 2, 5Ј-GGAAGCTATTCTGGGCCTCT-3Ј and 5Ј-GCAGCTTTATTTGGGT-GCTT-3Ј; mouse Irf6 promoter SMAD BS 3, 5Ј-TGTGCT -ATTAGCCCCAACCT-3Ј and 5Ј-TGTAGGGGGTTGAGTGTGGT-3Ј; mouse Irf6 promoter MEF2 BS, 5Ј-CGATCACAACACCAATCTGC-3Ј and 5Ј-GACAGGCTGTGCACTCTTGA-3Ј, mouse p21 promoter p63 BS 1, 5Ј-CTTAGCGCAGAGCGGTTC-3Ј and 5Ј-ACCTCCTCGCCTGT -CCTCTA-3Ј; and mouse p21 promoter p63 BS 2, 5Ј-TGGTCT -CCATCGGAATAGGT-3Ј and 5Ј-TGTTTGCCTAACTTGCTGGA-3Ј. Positions of PCR fragments correspond to National Center for Biotechnology Information (NCBI) mouse genome Build 33.1.
Histological examination
Hematoxylin and Eosin (H&E), immunohistochemical and 5-bromo-2Ј-deoxyuridine (BrdU) staining were performed as described previously (Iwata et al., 2012; Iwata et al., 2010) . Antibodies used for immunohistochemistry were rabbit polyclonal antibodies against p21 (Santa Cruz Biotechnology), IRF6 (Aviva Systems Biology), phosphorylated histone H3 (Millipore) and Lex/SSEA1 (FUT4 -Mouse Genome Informatics) (Cell Signaling Technology), and mouse monoclonal antibody against p63 (Santa Cruz Biotechnology). Fluorescence images were obtained using a fluorescence microscope (Model IX71, Olympus).
Immunoblot analysis
Immunoblots were performed as described previously (Iwata et al., 2006; Iwata et al., 2010) . Antibodies used for immunoblotting were rabbit polyclonal antibodies against IRF6 (Aviva Systems Biology) and p21 (Abcam), and mouse monoclonal antibodies against p63 (Santa Cruz Biotechnology) and GAPDH (Chemicon).
Palatal shelf organ culture
Timed pregnant mice were sacrificed at E13.5. Genotyping was carried out as described above. The palatal shelves were microdissected and cultured in serum-free chemically defined medium as previously described (Ito et al., 2003; Xu et al., 2008) . After 48 or 72 hours in culture, palates were harvested, fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4), and processed. For p63 experiments, palatal shelves were transfected with small interfering RNA (siRNA) duplexes (500 nM) for p63 or control (Santa Cruz Biotechnology). The 500 nM siRNA solutions were prepared by diluting a siRNA stock (10 μM) in BGJb medium containing Oligofectamine (0.3%) (Invitrogen). The siRNA mixture in transfection medium was changed every 24 hours and incubated with palatal shelves up to 72 hours after siRNA treatment at 37°C in a CO 2 incubator. For experiments with p21, palatal shelves were transfected with a GFP-tagged p21 overexpression or control vector (Origene). The 2-μg p21 transfection solutions were prepared in BGJb medium containing Lipofectamine LTX and PLUS reagents (Invitrogen) according to the manufacturer's protocol. The p21 transfection mixture was changed every 24 hours and incubated with palatal shelves up to 72 hours after transfection at 37°C in a CO 2 incubator. All experiments were performed with at least five samples.
Cell culture
Primary mouse keratinocytes were isolated from newborn mice and cultured in dermal cell basal medium (ATCC) supplemented with the Keratinocyte Growth Kit (ATCC). Primary mouse keratinocytes (2×10 6 cells) were plated in a 60-mm cell culture dish until the cells reached 60-80% confluence. Tgfbr2 and Irf6 siRNA duplexes were purchased from Santa Cruz Biotechnology. siRNA mixture in transfection medium was incubated with cells for 7 hours at 37°C in a CO 2 incubator, as described previously (Iwata et al., 2010) .
Quantitative reverse transcription PCR (RT-PCR)
Total RNA was isolated from dissected mouse MEE at E14.5 with the QIAshredder and RNeasy Micro Extraction Kit (QIAGEN), as described previously (Iwata et al., 2010) . The following PCR primers were used: Irf6, 5Ј-AGGGCTCTGTCATTAATCCAG-3Ј and 5Ј-TGATTCGGGGCT -GCAGTTTC-3Ј; p21 (Cdkn1a), 5Ј-AGCCTGAAGACTGTGATGGG-3Ј and 5Ј-AAAGTTCCACCGTTCTCGG-3Ј; ΔNp63, 5Ј-CAAAACCC -TGGAAGCAGAAA-3Ј and 5Ј-GAGGAGCCGTTCTGAATCTG-3Ј; and Gapdh, 5Ј-AACTTTGGCATTGTGGAAGG-3Ј and 5Ј-ACACATTG -GGGGTAGGAACA-3Ј.
Scanning electron microscopic (SEM) analysis
Samples were fixed with a modified Karnovsky fixative solution [2% paraformaldehyde and 2.5% glutaraldehyde in 0.067 M cacodylate buffer (pH 7.4)] for two days. After dehydration through a graded ethanol series, samples were critical-point dried in a Balzer Union apparatus (FL-9496), ion-sputtered with platinum-palladium (10-15 nm), and observed in JEOL JSM-6390 low vacuum scanning electron microscope (JEOL USA, MA, USA) at a low accelerating voltage of 10 kV.
Whole-mount skeletal staining and micro-CT analysis
The three-dimensional architecture of the skeleton was examined using a modified whole-mount Alcian Blue-Alizarin Red S staining protocol as previously described (Ito et al., 2003; Iwata et al., 2012) . Micro-CT analysis was performed using SCANCO μCT 50 (nanoCT) at the University of Southern California Molecular Imaging Center. The data were collected at a resolution of 10 μm. The reconstruction was performed using AVIZO 7.0 (Visualization Sciences Group).
Statistical analysis
A two-tailed Student's t-test was applied for statistical analysis. For all graphs, data are represented as mean±s.d. A P-value of less than 0.05 was considered statistically significant.
RESULTS
TGFβ signaling in the MEE regulates Irf6 expression during palatal fusion
Loss of TGFβ signaling in the basal epithelium in mice (Tgfbr2 fl/fl ;K14-Cre) results in diminished Irf6 expression and failure of apoptosis in MEE cells, followed by MEE persistence, suggesting that TGFβ-mediated Irf6 expression might play a role in degeneration of the MEE (Xu et al., 2006) . The MEE is composed of a basal columnar cell layer covered by flat cells that constitute the periderm (Cuervo and Covarrubias, 2004) . Irf6 is expressed in the periderm at E13.5, and Irf6 expression shows an obvious and consistent transition from the periderm to regions of the basal epithelial layer at E14.5 (Fig. 1E ) or MEE disappearance (Fig. 1H ) in control samples, indicating that SMAD and p38 MAPK activation are functionally redundant in regulating Irf6 expression and MEE disappearance.
Next, we analyzed the sequence of the mouse Irf6 gene (including 2.5 kb upstream and 2.5 kb downstream of the transcription start site). The mouse Irf6 genomic region has 43 potential SMAD recognition sites (three of which are conserved in at least six mammals) ( Fig. 1J ; supplementary material Table S1 ). The MEF2 transcription factor is regulated by the p38 MAPK pathway (Han and Molkentin, 2000; Toro et al., 2004) . We found a potential MEF2 recognition site in the Irf6 genomic region (Fig. 1J ). We performed chromatin immunoprecipitation (ChIP) assays to test whether SMAD and MEF2 could bind to the promoter region of Irf6. Binding sites for SMAD (SMAD binding site 1: −274 bp to −271 bp; site 2: −1695 bp to −1692 bp; site 3: −2375 bp to −2372 bp) and MEF2 (MEF2 binding site: −1387 bp to −1375 bp) immunoprecipitated with SMAD4 or MEF2 antibodies, but not with control antibody (Fig. 1K) . Taken together, our results suggest that Irf6 gene expression is regulated by both SMAD and p38 MAPK pathways.
Next, we investigated the functional significance of Irf6 in regulating the disappearance of MEE cells during palatal fusion. Because homozygous mutation of Irf6 results in severe intraoral epithelial adhesion, it is not known whether Irf6 is crucial for palatal (Ingraham et al., 2006; Richardson et al., 2006) . To investigate the fate of the MEE in Irf6 R84C/R84C mice, we used the ex vivo organ culture system. E13.5 wild-type control (n=17) and Irf6 +/R84C (n=39) palate explants fused and the MEE disappeared following two days of culture ( Fig. 2A,B) . By contrast, Irf6 R84C/R84C mutant (n=19) palatal shelves failed to fuse (Fig. 2C ) and the MEE persisted with continuous cell proliferation (Fig. 2D-F) and compromised cell death (Fig. 2G-I MEE cells during palatal fusion (Fig. 2J,K) . The MEE in control and Irf6 +/R84C explants disappeared completely following three days in culture; however, the MEE persisted in Irf6 R84C/R84C explants (supplementary material Fig. S2 ). These data indicate that IRF6 is crucial for MEE disappearance during palatal fusion. penetrance (n=19/19) (supplementary material Fig. S3) +/R84C mice in detail by scanning electron microscopy (SEM), and detected compromised rugae formation (Fig. 3G,H) . By histological analysis, we found that all Smad4 fl/fl ;K14-Cre;Irf6 +/R84C mice exhibited submucous cleft palate at birth with persistence of the MEE (n=19/19) and in some cases a stretched epithelial bridge (n=6/19) (Fig. 3I-O) . Taken together, our findings suggest that a genetic interaction between Smad4 and Irf6 is responsible for MEE disappearance during palatal fusion. 
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TGFβ-mediated Irf6 activity during palatogenesis fusion
Genetic interaction between
Rescue of palatal fusion in
2-fold) in the MEE of K14-Irf6
Tg mice compared with control (Fig. 4B) . Moreover, we confirmed the overexpression of IRF6 protein in the MEE by immunoblotting (Fig. 4C,D) and immunostaining ( Fig. 4E) Fig. S4 ). Although these Irf6 transgenic mice exhibited severe calvarial defects and hypoplasia of the palatine bones (Fig. 4J,M) , their palatal shelves fused normally without obvious cleft palate or persistence of the MEE (Fig. 4J) . Palatal fusion appeared to be unaffected in all K14-Irf6 Tg mice (n=146) ( Fig. 4F-M Tg mice (Fig. 5B,C) . In addition, Tgfbr2 fl/fl ;K14-Cre mice have submucous cleft palate throughout the anterior to posterior regions of the hard palate, based on histology (Fig. 5K) . At E15.5 and E16.5, the MEE disappeared in control mice, whereas MEE persistence was detectable in Tgfbr2 fl/fl ;K14-Cre mice (Fig. 5D,E,G,H) . Tgfbr2 fl/fl ; Irf6 Tg mice show a one-day delay in the disappearance of the MEE (Fig. 5F,I ). In histological sections, we detected MEE persistence (n=14/14) corresponding with the groove in the midline of the palate in Tgfbr2 fl/fl ;K14-Cre mice (Fig. 5K) . Proper apoptotic degradation of the MEE was restored in Tgfbr2 fl/fl ; Irf6 Tg mice (n=7/7), based on histological analysis (Fig. 5L) , indicating that TGFβ-mediated Irf6 signaling is functionally important and sufficient for MEE disappearance.
IRF6 regulates MEE disappearance via p21 expression
Apoptosis is one of the ultimate fates of the MEE during palatal fusion (Cuervo and Covarrubias, 2004) . Loss of Tgfbr2 in the 1225 RESEARCH ARTICLE TGFβ-mediated Irf6 activity during palatogenesis epithelium results in absence of apoptosis and maintenance of proliferation in MEE cells (Xu et al., 2006) . We analyzed the cellular defect in persistent MEE cells by assaying both cell proliferation and apoptosis activities. We found that altered cell proliferation in the MEE was restored in Tgfbr2 fl/fl ;K14-Cre;Irf6 Tg mice to a level comparable to the control (Fig. 6A-D) . Similarly, we found that altered apoptotic activity in the MEE was also restored in Tgfbr2 fl/fl ;K14-Cre;Irf6 Tg mice compared with the control (Fig. 6E-H) . Thus, our data demonstrate that loss of Tgfbr2 results in compromised Irf6 expression, continuous cell proliferation, and failure of apoptosis in MEE cells, indicating that TGFβ-mediated Irf6 expression plays a role in the disappearance of the MEE. We previously reported that p21 (also known as Cdkn1a) was decreased in the MEE of Tgfbr2 fl/fl ;K14-Cre mice (Xu et al., 2008) . We hypothesized that p21 expression might be regulated by the TGFβ-mediated IRF6 pathway. To investigate p21 expression, we performed immunohistochemical (Fig. 6I-K) , immunoblotting ( Fig. 6L ) and quantitative RT-PCR (Fig. 6M,N) analyses. We found that p21 expression was restored in E14. Previous studies have demonstrated that IRF6 induces degradation of the p63 isoform ∆Np63 and that this is linked with the pathogenesis of VWS and PPS (Moretti et al., 2010; Thomason et al., 2010) . In addition, ∆Np63 represses transcription of p21 in vitro and in vivo (Laurikkala et al., 2006; Welsh and O'Brien, 2009; Westfall et al., 2003) . Because there is no conserved IRF6-binding site in the promoter-proximal genomic region of p21 (in at least six mammals, 5 kb upstream and 5 kb downstream of the TSS), we hypothesized that IRF6 might regulate p21 expression via ∆Np63. ∆Np63 is only expressed in the basal epithelial layer during palate formation . Indeed, increased ∆Np63 expression was detectable in basal epithelial cells in Tgfbr2 fl/fl ;K14-Cre mice, consistent with a TGFβ-mediated IRF6/∆Np63/p21 signaling cascade at E14.5 and E15.5 (Fig. 7A-F) . Moreover, ∆Np63 expression was reversed by overexpression of Irf6 (Fig. 7C,F) . We also evaluated ∆Np63 expression levels in control, Tgfbr2 fl/fl ;K14-Cre and Tgfbr2 fl/fl ;K14-Cre;Irf6 Tg mice by immunoblotting (Fig. 7G) . To confirm that p21 expression is regulated by p63, we analyzed the mouse p21 promoter region (2.5 kb upstream and 2.5 kb downstream of the TSS), and found two potential p63-binding sites in the mouse genomic region of p21 (Fig. 7H) . We performed ChIP analysis to test whether p63 could bind to the genomic region of p21, and found that the p21 genomic
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Development 140 (6) region immunoprecipitated with the p63 antibody at p63-binding site 1 (+727 bp to +746 bp), but not at p63-binding site 2 (−436 bp to −455 bp) (Fig. 7I) . These results indicate that p21 expression is likely to be regulated through the TGFβ/IRF6/∆Np63 signaling cascade. Finally, we investigated the functional significance of the IRF6/p63/p21 signaling cascade using an ex vivo organ culture system. We found that either reduction of p63 or overexpression of p21 could restore the degeneration of the MEE (Fig. 8A-F) . In addition, primary mouse keratinocytes were treated with Tgfbr2, Irf6 or control siRNA (Fig. 8G) . After siRNA knockdown for Tgfbr2, gene expression of Irf6 and p21 was significantly decreased and p63 gene expression was significantly (P<0.05) upregulated. Similarly, Irf6 siRNA knockdown resulted in downregulation of Irf6 and p21 gene expression and upregulation of p63 gene expression. Previous studies indicate that p63 expression is upregulated in E14.5 Irf6 R84C/R84C palates (Thomason et al., 2010) and siRNA knockdown for Irf6 results in upregulated p63 expression in human keratinocytes (Moretti et al., 2010) . Therefore, we investigated whether p63 expression was altered in Irf6 R84C/R84C palates. The expression of p63 was increased in Irf6 R84C/R84C palates, consistent with previous findings (Fig. 8H,I ). Collectively, these data suggest that p21 expression is regulated through a TGFβ/IRF6/∆Np63 signaling cascade (Fig. 8J) .
DISCUSSION
Submucous cleft palate, which can result from MEE defects during palatal fusion, is one of the most common forms of cleft palate in humans, but the molecular and developmental mechanism of submucous cleft palate are not well studied, in part because of the paucity of animal models that exhibit this phenotype (Funato et al., 2012; Pauws et al., 2009) . MEE persistence affects palatal bone formation in the hard palate and muscle development in the soft palate; consequently, patients with submucous cleft palate need surgical and other procedures to develop precise physiological functions such as speech and swallowing.
We have generated an animal model in which loss of TGFβ signaling in MEE cells results in submucous cleft palate (Xu et al., 2006) . In this study, we show that TGFβ-mediated Irf6 expression is crucial for the fate of MEE cells. MEE degeneration in Tgfbr2 fl/fl ;K14-Cre mice was restored by overexpression of Irf6, indicating that Irf6 is functionally important for the MEE disappearance mediated by TGFβ signaling. Previous studies indicate that mice with loss of Irf6 function exhibit cleft palate owing to failure of palatal shelf elevation resulting from adhesion between the palatal shelves and the tongue, following a defect in epithelial differentiation (Ingraham et al., 2006; Richardson et al., 2006) . Because of the failure of palatal elevation in Irf6 R84C/R84C mice, we were previously not able to investigate the role and function of Irf6 during MEE disappearance fully. In this study, using an ex vivo organ culture system, we show for the first time that Irf6 R84C/R84C mutation results in the absence of apoptosis and the maintenance of proliferation in the MEE, indicating that Irf6 is crucial for MEE cell fate during palatal fusion. Although heterozygous Irf6 mutant mice have normal palate formation, a combination of loss of Smad4 and inhibition of p38 MAPK only led to ~50% reduction of Irf6 expression and persistence of the MEE in ex vivo organ culture. This result suggests that there are other factors or signaling pathways that might regulate Irf6 expression in addition to SMAD4/p38 MAPK signaling pathways 1227 RESEARCH ARTICLE TGFβ-mediated Irf6 activity during palatogenesis (Ferretti et al., 2011; Letra et al., 2012) . A recent study has shown that integration of IRF6 and the Notch ligand jagged 2 signaling is essential for controlling palatal adhesion and fusion during palatogenesis (Richardson et al., 2009) . Interestingly, overexpression of Irf6 in Tgfbr2 fl/fl ;K14-Cre mice did not rescue the developmental defects in the palatal mesenchyme (supplementary material Fig. S5 ), suggesting that the TGFβ-mediated IRF6 signaling cascade plays a cell-autonomous role in regulating the fate of MEE cells during palatal fusion and that TGFβ regulates other downstream target genes that control the development of muscles in the soft palate through tissue-tissue interactions. Furthermore, using mutant mouse models, we found that TGFβ signaling regulates Irf6 and p21 expression and MEE disappearance via both SMAD-dependent and -independent pathways during palatal fusion.
SMAD4 mutations have been found in patients with unselected hereditary hemorrhagic telangiectasia (HHT), which is an autosomal dominant disease of vascular dysplasia (Gallione et al., 2006) . The symptoms of HHT include epistaxis, telangiectases, and arteriovenous malformations, which are most often found in the lungs, brain, liver and gastrointestinal tract. In addition, SMAD4 mutations have been identified in families with juvenile polyposis, aortophathy, and mitral valve dysfunction (Andrabi et al., 2011 humans with IRF6 mutation, whereas Irf6 +/R84C mice do not show digit developmental defects. These results suggest that a compromised SMAD-dependent, TGFβ-mediated IRF6 signaling cascade might be responsible for developmental defects associated with PPS. Furthermore, an impaired TGFβ/IRF6 signaling cascade may cause submucosal cleft palate.
The secondary palate is divided into two parts: the anterior bony hard palate, which is about two-thirds of the secondary palate and is composed of bone, and the posterior fleshy soft palate, which is about one-third of the secondary palate and is composed of muscles. Our previous study suggests that loss of Tgfbr2 in the epithelium causes cleft soft palate owing to failure of muscle development and misorientation of muscle fibers (Xu et al., 2006 Tg mice. One possible explanation is that there are differential gene expression patterns in the anterior versus the posterior in the MEE. Expression of Irf6, p63 and Tgfb3 is detectable throughout the oral epithelia in wild-type mice with no variation along the antero-posterior axis of the secondary palate Richardson et al., 2009; Yang et al., 2008) . However, gene expression of Tgfb3 was compromised specifically in the posterior palate in Irf6 R84C/R84C mice, indicating that Tgfb3 expression is differentially regulated between the anterior and posterior MEE (Richardson et al., 2009 ). It also suggests that IRF6
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Development 140 (6) provides a feedback in regulating TGFβ signaling in the posterior region of developing palate. WNT/β-catenin signaling acts upstream of Irf6 in the lip epithelium during lip fusion (Ferretti et al., 2011) . A previous study has shown that loss of WNT/β-catenin signaling results in downregulation of TGFβ, whereas expression of stabilized β-catenin in the palatal epithelium can cause ectopic Tgfb3 expression and fusion of the palatal shelf and mandible (He et al., 2011) . This study clearly demonstrates that a precisely controlled TGFβ signaling level is crucial for regulating the fate of MEE cells during palatal fusion. Ablation of p63 results in diminished Irf6 expression in the palate (Moretti et al., 2010; Thomason et al., 2010) , and IRF6 can regulate ΔNp63 degradation in human keratinocytes (Moretti et al., 2010) . However, we found that upregulated p63 expression in wild-type mice did not affect the expression of Irf6 in MEE cells (data not shown), indicating that there is no apparent feedback loop from upregulated p63 to Irf6 expression.
In summary, our data indicate that a combination of genetic mutations in Irf6 and Smad4 cause submucous cleft palate and that TGFβ-mediated IRF6 activity is crucial for MEE disappearance. This is a significant advancement in our understanding of the mechanism of TGFβ signaling-associated cleft palate. Our findings that TGFβ-mediated Irf6 expression is responsible for MEE disappearance and that overexpression of Irf6 normalizes MEE cell fate determination in Tgfbr2 fl/fl ;K14-Cre mice might provide potential therapeutic approaches for individuals with altered TGFβ signaling and submucous cleft palate. In addition, we propose that combined mutations in IRF6 and SMAD4 in humans might be useful diagnostic biomarkers for patients with cleft palate. ;K14-Cre palates. IRF6 expression is regulated through both SMAD and p38 MAPK pathways. In the absence of TGFβ receptor type II (TβRII), IRF6 expression decreases. ΔNp63 expression increases in the absence of TβRII resulting in reduced p21 expression in the palatal epithelium. Altered TGFβ-IRF6-ΔNp63-p21 activity results in the persistence of the MEE. P, phosphorylated. Error bars represent s.d. *P<0.05; **P<0.01. Scale bars: 50 μm. RESEARCH ARTICLE TGFβ-mediated Irf6 activity during palatogenesis
